Replies to post #243484 on Biotech Values

[DewDiligence]

Even after today’s bounce, UBX is down 92% from its 2018 IPO (#msg-140490600). DME and AMD are huge markets, but there’s now competition from biosimilars to the anti-VEGF drugs.

[DewDiligence]

UBX -45% on phase-2 failure in wet AMD:

https://ca.finance.yahoo.com/news/unity-biotechnology-announces-results-phase-113000015.html

Patients treated with UBX1325 had a mean change from baseline in BCVA of -0.8 ETDRS letters at 24 weeks compared to +3.1 ETDRS letters in the aflibercept [Eylea] control arm…

…The ENVISION study did not meet the non-inferiority margin of -4.5 letters compared to aflibercept with an 85% confidence interval.

[DewDiligence]

UBX reports 48w phase-2 data_in DME—plans_head-to-head_phase-2b_vs Eylea:

https://finance.yahoo.com/news/unity-biotechnology-announces-positive-48-110000280.html

All this despite the company’s failure in a phase-2 head-to-head vs Eylea in wet AMD (#msg-171545325). Zebra’s Law?

p.s. The stock is down 86% from its 2018 IPO (#msg-140490600).